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Under the subheading 'Rat model of cardiac fibrosis' the second paragraph should read:
Rats were randomly divided into five groups (ten per group) for treatment: control; myocardial fibrosis (isopro terenol
[Iso]); and low-, middle-, and high-dose RLX (0.2, 2, and 20 μg⋅kg -1 ⋅day -1 , respectively). RLX was obtained from Peprotech, Rocky Hill, NJ, USA (product number 130-15).
For the Iso-model, on days 1-6, Iso (5 mg⋅kg -1 ⋅d -1 ; SigmaAldrich Co., St Louis, MO, USA) was injected subcutaneously in the rats. In the therapeutic groups, Iso administration was the same as in the Iso-model group, and RLX at different concentrations (0.2, 2.0, and 20 μg⋅kg -1 ⋅day -1 ) were injected at the same time as Iso injection and lasted for 6 days, then RLX injection was continued for another 8 days. The same volume of saline was injected for controls.
